https://www.selleckchem.com/pr....oducts/dibutyryl-cam
Further stratified analysis in PLC, LUAD, and LUSC datasets, we only identified that TP53 was significantly associated with OS in patients with surgically resected stage I lung adenocarcinoma. TP53 mutations are potentially markers of poor prognosis for stage I lung adenocarcinoma patients. The mutation status of this gene may contribute to clinical decision-making with respect to selecting patients who may benefit from adjuvant therapy. TP53 mutations are potentially markers of poor prognosis for stage I lung adenoca
Like
Comment
Share
